Susan Horvath
CIK 1322846 · V.P. of Finance & CFO · last filed 2024-10-03
Susan Horvath is a V.P. of Finance & CFO who has filed 14 SEC Form 4 insider transactions across 2 companies since 2020. Current disclosed insider exposure totals $198 across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$198
2
14
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PBLA | V.P. of Finance & CFO | 17,880 | $0.01 | $198 | $0 | 4 | 2023-03-29 |
| Panbela Therapeutics, Inc. (SNBP) Delisted | V.P. of Finance & CFO | 13,436 | — | — | $0 | 1 | 2020-09-01 |
Recent Filings
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-10-03 | — | Grant (A) | — | $0 | |
| 2023-03-29 | PBLA | Grant (A) | — | $0 | EDGAR |
| 2023-02-01 | PBLA | Buy (P) | +4,444 | $0 | EDGAR |
| 2021-09-15 | PBLA | Grant (A) | — | $0 | EDGAR |
| 2021-04-01 | PBLA | Grant (A) | — | $0 | EDGAR |
| 2020-09-01 | Panbela Therapeutics, Inc. (SNBP) Delisted | Buy (P) | +2,424 | $0 | EDGAR |
| 2020-06-26 | — | Grant (A) | — | $0 | |
| 2020-06-09 | — | Buy (P) | +2,500 | $0 | |
| 2019-09-26 | — | Grant (A) | — | $0 | |
| 2019-09-04 | — | Buy (P) | +1,428 | $0 |